Table 2.
HuR expression, localisation, and associations with clinicopathological features and target molecules as well as patients' overall survival in studies investigating tissue samples.
| Study | N | HuR localisation | Correlations with | |||
|---|---|---|---|---|---|---|
| Nuclear | Cytoplasmic | Clinicopathological features | Other molecules | Patients' overall survival | ||
| OSCCs | ||||||
| Cha et al. [64] | 95 | 91.6% (87/95) | 71.6% (68/95) | Grade | Nuclear and cytoplasmic with IAP2 | Cytoplasmic HuR adverse prognosticator |
| Cha et al. [63] | 103 | 93.2% (96/103) | 69.9% (72/103) | Gender, grade, lymph node, and distant metastasis | Cytoplasmic HuR with COX-2 | Cytoplasmic HuR adverse prognosticator |
| Kim et al. [68] | 96 | 91% (83/96) | 60% (54/96) | Lymph node metastasis | — | Not correlated |
|
| ||||||
| LSCCs | ||||||
| Cho et al. [44] | 39 | 100% (39/39) | 66.6% (26/39) | None | Cytoplasmic HuR with COX-2 | — |
|
| ||||||
| Thyroid lesions | ||||||
| Giaginis et al. [98] | 98 | Presence in 80% (78/98), higher expression in 43% (42/98) | ||||
| Benign | 48 | Predominantly nuclear, higher expression in 29% (14/48) | (i) Ki-67 in follicular cells (ii) COX-2 (stronger in benign) |
— | ||
| Malignant | 50 | Predominantly cytoplasmic, higher expression in 56% (28/50) | Lymphatic invasion (trend) | — | ||
| Baldan et al. [97] | 104 | |||||
| Normal samples | 12 | (i) ↑ nuclear in all tumours (ii) ↑ cytoplasmic in nontumour tissues versus FAs or PTCs, FTCs and ATCs |
— | — | — | |
| Follicular adenomas | 25 | — | — | — | ||
| Carcinomas (PTC, FTC, and ATC) | 67 | — | — | — | ||
|
| ||||||
| Salivary gland tumours | ||||||
| Cho et al. [100] | 46 | |||||
| Pleomorphic adenoma | 28 | 53.6% (15/28) | 35.7% (10/28) | — | — | — |
| Mucoepidermoid carcinoma | 18 | 77.78% (14/18) | 72.22% (13/18) | — | Cytoplasmic HuR with COX-2 | — |